Latest

Australian biotech company Mesoblast Ltd (ASX: MSB, Nasdaq: MESO) has released encouraging new data for its cell therapy Ryoncil™ (remestemcel‑L), used to treat steroid-refractory acute graft-versus-host disease (SR‑aGvHD). The update was presented at the 2026 Tandem Meetings  of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Centre for Blood and Marrow Transplant Research (CIBMTR) in Utah. Key Clinical Findings The real-world data show high sur